Slow And Steady Wins

A few years back, a Merck (MRK) executive was giving a presentation to Wall Street analysts when someone’s phone started ringing with the old Nokia tune.

Without missing a beat, the executive quipped, “Well, at least that’s one technology that had a longer patent life than most of our drugs.”

The room erupted in laughter, but it highlighted a fundamental truth about Big Pharma. They’re constantly racing against the clock, knowing their biggest moneymakers have expiration dates stamped right on them.

Speaking of racing against time, let’s circle back to Merck and why it deserves your attention right now, even as it wrestles with some serious headwinds that would make most companies reach for the antacids.

Last week, while everyone was talking about Eli Lilly’s (LLY) weight-loss drug drama and Warren Buffett’s surprise romance with UnitedHealth Group (UNH), Merck quietly put together a respectable rally that caught most folks napping.

The stock’s up about 9% since April, dividends included, and trading around $84 with all the excitement of watching grass grow.

Merck also just delivered second-quarter results that perfectly embodied the phrase “good enough.”

They beat earnings expectations with $2.13 per share versus the $2.03 consensus, which sounds impressive until you realize their revenue of $15.8 billion missed estimates by a modest $60 million.

The real story hiding in these numbers is more complex than assembling furniture without instructions.

The company’s facing a pharmaceutical soap opera right now.

On one side, you’ve got Gardasil sales plummeting 54% faster than your enthusiasm for New Year’s resolutions, which explains why investors initially yawned at the earnings beat.

On the flip side, their oncology and cardiovascular portfolios are performing like seasoned professionals, with Keytruda revenue growing 9% annually despite everyone wringing their hands about its 2028 patent expiration.

But here’s where it gets interesting for those of us who actually read beyond the headlines. Management is planning a $3 billion cost-cutting initiative tied to that Keytruda patent cliff, though they’re diplomatically calling it more of a “hill” than a “cliff.”

I’ve heard politicians use less creative spin, but the underlying message is clear: they’re not planning to go quietly into pharmaceutical retirement when their blockbuster drug loses patent protection.

New products like Winrevair are showing promising early performance, and executives are touting pipeline growth across 80 trials.

Meanwhile, the company is projecting revenue near $65 billion this year, which isn’t exactly pocket change even in today’s inflated economy.

From a valuation standpoint, Merck’s trading at a discount. The stock’s sporting a forward price-to-earnings ratio sitting around 12 times expected earnings, which is conservative enough to make your accountant smile.

Add in a solid 4% dividend yield that’s above the long-term average, and you’ve got an income play that actually pays you to wait around.

The technical picture tells a story of patient accumulation rather than explosive momentum.

Shares found solid support in the low $80s earlier this year and recently broke above their 50-day moving average.

The 200-day average still looms overhead like storm clouds, but the overall trend is pointing in the right direction for those willing to exercise some patience.

Risk-wise, you’re looking at the usual pharmaceutical suspects.

There’s uncertainty around how effectively they’ll execute that $3 billion reinvestment plan, plus the ever-present question mark around post-Keytruda performance.

Gardasil faces potential tariff headwinds, though we’re still waiting for the current administration to clarify its pharmaceutical trade policies.

The options market is pricing in about a 5.2% earnings-related move for the October release, which suggests traders aren’t expecting any earth-shattering surprises.

That’s probably appropriate given Merck’s tendency toward steady, predictable performance as opposed to roller coaster updates.

Merck represents that increasingly rare breed of large-cap pharmaceutical companies that combines reasonable valuation, consistent dividend income, and enough pipeline diversity to weather the inevitable patent cliff challenges.

It’s not going to make you rich overnight, but it might just keep paying dividends while you sleep, which strikes me as a pretty decent deal in today’s market environment.

Sometimes the tortoise really does beat the hare, especially when the tortoise pays you 4% annually for the privilege of watching the race.